388082-75-5

Basic information

• Product Name: 2-Furancarboxaldehyde,5-[4-[[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]aMino]-6-quinazolinyl]-, Mono(4-Methylbenzenesulfonate)
• Synonyms: 2-Furancarboxaldehyde,5-[4-[[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]aMino]-6-quinazolinyl]-, Mono(4-Methylbenzenesulfonate);5-[4-[[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]amino]-6-quinazolinyl]-2-furancarbaldehyde tosylate
• CAS NO: 388082-75-5
• Molecular Formula: C33H25ClFN3O6S
• Molecular Weight: 646
• Mol File: 388082-75-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Furancarboxaldehyde,5-[4-[[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]aMino]-6-quinazolinyl]-, Mono(4-Methylbenzenesulfonate)(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Furancarboxaldehyde,5-[4-[[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]aMino]-6-quinazolinyl]-, Mono(4-Methylbenzenesulfonate)(388082-75-5)
• EPA Substance Registry System: 2-Furancarboxaldehyde,5-[4-[[3-chloro-4-[(3-fluorophenyl)Methoxy]phenyl]aMino]-6-quinazolinyl]-, Mono(4-Methylbenzenesulfonate)(388082-75-5)

Safety Data

• Hazardous Substances Data: 388082-75-5(Hazardous Substances Data)

Upstream product

• 104-15-4 toluene-4-sulfonic acid 
• 231278-84-5 5-(4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)quinazolin-6-yl)furan-2-carbaldehyde 
• 98-01-1 furfural 
• 7647-10-1 palladium(II) chloride 
• 231278-20-9 N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-iodoquinazolin-4-amine 
• 13529-27-6 2-(diethoxymethyl)furan 
• 202197-25-9 {4-[(3-fluorobenzyl)oxy]phenyl}amine 
• 27329-70-0 5-formylfurane-2-boronic acid 
• 202197-26-0 3-chloro-4-(3-fluorobenzyloxy)aniline 
• 98556-31-1 4-chloro-6-iodoquinazoline 
• 16064-08-7 6-iodoquinazolin-4(3H)-one 

Relevant articles and documents

SALTS OF LAPATINIB

The present invention provides novel dioxalate salt of lapatinib, process for its preparation and pharmaceutical compositions comprising it. The present invention also provides novel monobesylate salt of lapatinib, process for its preparation and pharmaceutical compositions comprising it. The present invention further provides a process for the preparation of monohydrate form of lapatinib ditosylate. The present invention further provides a process for the preparation of anhydrous form of lapatinib ditosylate.

LAPATINIB INTERMEDIATES

The invention provides lapatinib intermediates and improved processes for preparing lapatinib intermediates. The invention also provides processes for preparing lapatinib base and lapatinib ditosylate.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and an IGF-1R inhibitor to a mammal suffering from a cancer.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional EGFR and/or erbB-2 inhibitor. In particular, the method relates to methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional EGFR and/or erbB-2 inhibitor.

CANCER TREATMENT METHOD

Disclosed herein is a method of treating breast cancer that has metastasized to the brain in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to methods of treating bre

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and at least one additional anti-neoplastic compound. In particular, the method relates to a methods of treating cancers by administration of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof in combination with at least one additional anti-neoplastic compound.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal by administration of 4-quinazolinamines and pharmaceutical compositions containing the same. In particular, the method relates to a methods of treating cancers which are mediated by the tyrosine kinases EGFR and/or erbB2 by administration of N-{3-chloro-4-[(3-fluorobenzyl) oxy]phenyl}-6-[5-({[2-(methanesulphonyl) ethyl]amino} methyl)-2-furyl]-4-quinazolinamine and salts and solvates thereof.

CANCER TREATMENT METHOD

A method of treating cancer is described including administration of a pyrimidine derivative and a quinazoline derivative as well as a pharmaceutical composition including the same.

CANCER TREATMENT METHOD

The present invention relates to a method of treating cancer in a mammal and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering an erb family inhibitor and a PI3K and/or Akt inhibitor to a mammal suffering from a cancer.